<DOC>
	<DOCNO>NCT02635256</DOCNO>
	<brief_summary>Hypofractionated radiosurgery investigate trial appear safe feasible . Investigators initiate multicenter phase II prospective trial analyse feasibility ( toxicity ) hypofractionated radiosurgery 5 fraction patient localised prostate cancer , ineligible `` PREFERE trial '' hypothesis ratio patient late toxicity ≥ grade 2 1 year amount 2,8 % significant low 17.5 % .</brief_summary>
	<brief_title>Hypofractionated Radiosurgery Localised Prostate Cancer</brief_title>
	<detailed_description>Experimental radiosurgery prostate 5 fraction 7,00 Gy ( total application rate 35,00 Gy ) . Planned visit : Baseline , visit every radiation day four follow ups ( 4-6 week , 3 month , 6 month one year last day radiation ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Localised , histopathologically confirm Prostate Cancer ( cT13 N0 M0 ) Gleasongrade ≤7 Guidelinebased stag Age &gt; 75 year Age 7075 year either PSA &gt; 10 ng/ml and/or GleasonScore 7b and/or GleasonScore 7a &gt; 33 % take punch positve and/or cT &gt; 2a and/or prostate volume &gt; 60 cm³ PSA &lt; 15 ng/ml Volume prostate &lt; 80 cm³ IPSSScore ≤12 Written inform consent Indication treatment within PREFERE trial History prior pelvic radiotherapy Contraindication Fiducial marker implantation ( e.g . allergy gold ) , Immunosuppressive therapy Relevant comorbidity think adversely affect treatment compliance , Legal incapacity lack informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>hypofractionation</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>radiotherapy</keyword>
</DOC>